Shigetecvax logo v2-01.png
  • About us

  • Our Plan

  • Partners

  • News

  • Contact

  • More

    Use tab to navigate through the menu items.
    • All Posts
    • News
    • Events
    Search
    Eveliqure announces the start of a Phase 1 clinical study of its combined Shigella and ETEC vaccine
    EVI
    • Sep 24, 2020

    Eveliqure announces the start of a Phase 1 clinical study of its combined Shigella and ETEC vaccine

    ShigETEC is an orally administered vaccine candidate developed by Eveliqure.
    Eveliqure's effort to develop a Shigella-ETEC combination vaccine is supported by the Wellcome Trust
    EVI
    • Nov 5, 2019

    Eveliqure's effort to develop a Shigella-ETEC combination vaccine is supported by the Wellcome Trust

    Shigella-ETEC combination vaccine for travellers and children in resource poor countries is supported by the Wellcome Trust.
    “Success Story” series of the Austrian Research Promotion Agency (FFG)
    EVI
    • Oct 25, 2019

    “Success Story” series of the Austrian Research Promotion Agency (FFG)

    The SHIGETECVAX consortium and Eveliqure included in the “Success Story” series of the Austrian Research Promotion Agency (FFG)
    SHIGETECVAX Kick-off meeting
    EVI
    • Oct 15, 2019

    SHIGETECVAX Kick-off meeting

    The official kick-off meeting of the SHIGETECVAX project was held at the Eveliqure facilities in Vienna, Austria.
    EVI
    • Sep 12, 2019

    Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC

    SHIGETECVAX included in the Community Research and Development Information Service (CORDIS).
    EVI
    • Sep 10, 2019

    International partnership to advance the development of a new vaccine against Shigella and ETEC

    Horizon2020 award to consortium will support the testing of an innovative live attenuated vaccine in phase I clinical trials.

    Connect

    Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

    Thanks for subscribing! If you have any questions or would like to unsubscribe contact us at communication@euvaccine.eu.

    • LinkedIn - White Circle
    • Twitter - White Circle
    EU emblem_flag_yellow_high (1).jpg

    This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

    Privacy Policy  |  Imprint  |  Contact us  |  Back to top

    © 2022 European Vaccine Initiative. Designed by European Vaccine Initiative